{"schema_version":"1.0","type":"article","title":"The FDA Tone Has Shifted: Why Biotech’s Rebound Is Starting at the Regulatory Layer","url":"https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound-en.md","lang":"en","date":"2026-06-28","publish_at":"2026-06-28T08:50:00+08:00","updated_at":"2026-06-28","category":"商業分析系列","topic":"商業分析系列","tags":["FDA","Biotech rebound","Regulatory risk","Rare disease","Gene therapy","mRNA vaccines","M&A","Capital markets"],"summary":"Biotech’s recent rebound is not only a risk-on trade. FDA review signals, rare-disease flexibility, mRNA vaccine momentum, and renewed pharma M&A are changing how investors price clinical-stage assets.","key_points":[],"facts":[],"sections":["01 | Operation TrialBlazer: FDA Is Signaling That Review Efficiency Matters Again","02 | Moderna: The Same mRNA Flu Vaccine Suddenly Looks Different","03 | uniQure: Rare-Disease Gene Therapy Sees a Path Back to Accelerated Approval","04 | REGENXBIO: Navsunli Looks Like a Rare-Disease Review Barometer","05 | XBI’s Rebound Is Not Only About FDA. It Is Also About M&A Coming Back","Conclusion | The FDA Is Not Opening the Gates. It Is Letting Strong Data Be Seen Faster."],"references":[{"title":"[1] Barron’s","source":"[Biotech Shares Are Soaring]","date":"","url":"https://www.barrons.com/articles/biotech-shares-xbi-ff82f9cb"},{"title":"[2] FDA","source":"[Clinical Trials and Human Subject Protection]","date":"","url":"https://www.fda.gov/drugs/development-approval-process-drugs/clinical-trials-and-human-subject-protection"},{"title":"[3] FDA","source":"[Vaccines and Related Biological Products Advisory Committee]","date":"","url":"https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-and-related-biological-products-advisory-committee"},{"title":"[4] The Wall Street Journal","source":"[FDA Gives Third Rare-Disease Drug Another Shot, Regenxbio Says]","date":"","url":"https://www.wsj.com/tech/biotech/fda-will-reverse-rejection-of-third-rare-disease-drug-regenxbio-says-d8fff1fc"},{"title":"[5] REGENXBIO","source":"[RGX-121 / Navsunli program information]","date":"","url":"https://www.regenxbio.com/pipeline/rgx-121/"}],"images":[{"alt":"Operation TrialBlazer and biotech valuation logic","url":"https://drugnews.com.tw/assets/articles/fda-regulatory-shift-biotech-rebound-en/figure-01.png"},{"alt":"Moderna mRNA flu vaccine risk benefit shift","url":"https://drugnews.com.tw/assets/articles/fda-regulatory-shift-biotech-rebound-en/figure-02.png"},{"alt":"uniQure AMT-130 rare disease regulatory path","url":"https://drugnews.com.tw/assets/articles/fda-regulatory-shift-biotech-rebound-en/figure-03.png"},{"alt":"REGENXBIO Navsunli rare disease review signal","url":"https://drugnews.com.tw/assets/articles/fda-regulatory-shift-biotech-rebound-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/fda-regulatory-shift-biotech-rebound-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-28）。The FDA Tone Has Shifted: Why Biotech’s Rebound Is Starting at the Regulatory Layer。https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-06-28-fda-regulatory-shift-biotech-rebound.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}